Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Earnings

Review historical estimates and see whether a company has beaten or missed expectations.

Last Close
Jun 14 04:00PM ET
Dollar change
Percentage change
IndexRUT P/E- EPS (ttm)-2.26 Insider Own16.63% Shs Outstand54.48M Perf Week-43.93%
Market Cap19.14M Forward P/E- EPS next Y-0.81 Insider Trans-0.91% Shs Float45.58M Perf Month-53.94%
Income-122.54M PEG- EPS next Q-0.27 Inst Own43.74% Short Float5.05% Perf Quarter-60.14%
Sales16.94M P/S1.13 EPS this Y41.64% Inst Trans-0.34% Short Ratio5.66 Perf Half Y-70.83%
Book/sh0.55 P/B0.64 EPS next Y36.62% ROA-100.70% Short Interest2.30M Perf Year-89.58%
Cash/sh1.28 P/C0.27 EPS next 5Y- ROE-147.29% 52W Range0.42 - 4.45 Perf YTD-52.89%
Dividend Est.- P/FCF- EPS past 5Y-1.20% ROI-163.38% 52W High-92.13% Beta0.74
Dividend TTM- Quick Ratio5.20 Sales past 5Y115.17% Gross Margin73.75% 52W Low-16.67% ATR (14)0.08
Dividend Ex-Date- Current Ratio5.38 EPS Y/Y TTM-43.75% Oper. Margin-715.02% RSI (14)25.56 Volatility15.68% 12.16%
Employees55 Debt/Eq1.52 Sales Y/Y TTM-60.83% Profit Margin-723.49% Recom3.00 Target Price1.65
Option/ShortYes / Yes LT Debt/Eq1.52 EPS Q/Q-13.60% Payout- Rel Volume5.17 Prev Close0.44
Sales Surprise26.80% EPS Surprise-40.70% Sales Q/Q-65.37% EarningsMay 13 AMC Avg Volume406.41K Price0.35
SMA20-48.28% SMA50-51.54% SMA200-65.22% Trades Volume2,101,044 Change-21.10%
Date Action Analyst Rating Change Price Target Change
Jun-13-24Downgrade Stifel Buy → Hold $6 → $1
Jun-13-24Downgrade Needham Buy → Hold
Jun-13-24Downgrade H.C. Wainwright Buy → Neutral
Jun-13-24Downgrade Canaccord Genuity Buy → Hold $10 → $1
Mar-08-23Downgrade BofA Securities Neutral → Underperform $13 → $6
Mar-08-22Upgrade JP Morgan Neutral → Overweight $17 → $20
Nov-01-21Resumed Canaccord Genuity Buy $33
Aug-03-21Initiated JP Morgan Neutral $16
Apr-21-20Reiterated H.C. Wainwright Buy $30 → $33
Aug-12-19Reiterated H.C. Wainwright Buy $31 → $30
Jun-13-24 09:51AM
Jun-12-24 04:01PM
May-13-24 08:55PM
04:01PM Loading…
May-06-24 07:00AM
Apr-02-24 07:00AM
Mar-07-24 07:00AM
Mar-05-24 09:07AM
Mar-04-24 08:51PM
04:01PM Loading…
Feb-12-24 04:01PM
Jan-22-24 10:19AM
Dec-18-23 07:00AM
Nov-14-23 11:04AM
Nov-13-23 06:00PM
Nov-09-23 11:38AM
Nov-06-23 10:00AM
Nov-02-23 07:00AM
Oct-23-23 07:00AM
Sep-25-23 07:00AM
07:00AM Loading…
Sep-05-23 07:00AM
Aug-10-23 02:53AM
Aug-08-23 05:54AM
Aug-07-23 05:15PM
Aug-03-23 07:00AM
Aug-02-23 07:00AM
Jul-24-23 07:00AM
Jun-14-23 01:37PM
Jun-13-23 06:30AM
Jun-02-23 06:46PM
Jun-01-23 07:00AM
May-30-23 06:34PM
May-25-23 06:40AM
May-18-23 04:53PM
May-16-23 11:02AM
May-15-23 05:15PM
May-04-23 09:38AM
May-01-23 07:00AM
Apr-26-23 08:00PM
Apr-10-23 07:00AM
Apr-07-23 08:41AM
Mar-14-23 07:00AM
Mar-11-23 07:19AM
Mar-08-23 06:59AM
Mar-07-23 10:46AM
Mar-06-23 07:39PM
Feb-27-23 10:00AM
Feb-21-23 07:00AM
Feb-15-23 05:11AM
Feb-08-23 05:00PM
Jan-17-23 07:00AM
Jan-03-23 07:00AM
Dec-29-22 05:53AM
Nov-29-22 07:30AM
Nov-09-22 06:08AM
Nov-07-22 05:35PM
Nov-04-22 08:46AM
Nov-03-22 07:00AM
Nov-02-22 10:01AM
Oct-31-22 10:00AM
Oct-30-22 08:51AM
Oct-24-22 07:00AM
Oct-18-22 09:55AM
Oct-10-22 04:05PM
Sep-28-22 07:00AM
Sep-20-22 09:47AM
Sep-12-22 07:00AM
Sep-08-22 02:27PM
Sep-06-22 07:00AM
Aug-24-22 07:00AM
Aug-22-22 07:00AM
Aug-19-22 01:00AM
Aug-08-22 05:15PM
Aug-04-22 08:48AM
Aug-03-22 07:00AM
Aug-01-22 04:01PM
CARA Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors (KORs). Its portfolio includes opioid-based products, anesthetic-based drugs, and analgesics that targets to alleviate itch and pain. The company was founded by Derek T. Chalmers, Michael E. Lewis, and Frederique Menzaghi on July 2, 2004 and is headquartered in Stamford, CT.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Posner ChristopherPRESIDENT AND CEOMay 02 '24Sale0.753,9362,952176,585May 06 04:15 PM
Terrillion ScottSEC'Y; CHIEF COMPLIANCE & G.C.Apr 05 '24Sale0.832,7532,28588,247Apr 09 04:21 PM
Goncalves JoanaCHIEF MEDICAL OFFICERApr 05 '24Sale0.832,7532,28553,365Apr 09 04:22 PM
Posner ChristopherPRESIDENT AND CEOFeb 29 '24Sale0.895,8345,192180,521Mar 04 04:19 PM
Goncalves JoanaCHIEF MEDICAL OFFICERFeb 29 '24Sale0.893,2932,93156,118Mar 04 04:13 PM
Terrillion ScottSEC'Y; CHIEF COMPLIANCE & G.C.Feb 29 '24Sale0.893,2932,93191,000Mar 04 04:24 PM
Posner ChristopherPRESIDENT AND CEOFeb 08 '24Sale0.5335,57518,855186,355Feb 12 05:10 PM
Posner ChristopherPRESIDENT AND CEOFeb 01 '24Sale0.554,9812,740221,930Feb 05 04:26 PM
Posner ChristopherPresident and CEONov 02 '23Sale1.223,7964,631164,411Nov 03 04:37 PM
Posner ChristopherPresident and CEOAug 03 '23Sale3.074,30713,222168,207Aug 04 05:21 PM
Menzaghi Frederique Ph.D.Chief Scientific Off,SVP-R&DJun 23 '23Sale3.512,99310,505153,747Jun 27 04:08 PM
Goncalves JoanaChief Medical OfficerJun 23 '23Sale3.512,7239,55853,681Jun 27 04:07 PM
Terrillion ScottSec'y; Chief Compliance & G.C.Jun 23 '23Sale3.512,4838,71588,563Jun 27 04:09 PM